Alcohol Dependence Clinical Trial
Official title:
Feasibility and Tolerability of a Combination of Naltrexone and Baclofen for Alcohol Dependence: A Pilot Study.
The purpose of this research study is to learn about the use of a combination of two
medications, baclofen and naltrexone, for the treatment of alcohol dependence in men and
women ages 25-60 years old. Naltrexone is an FDA approved medication for treatment of
alcohol dependence. The most widely accepted idea for naltrexone's effect is that it reduces
the alcohol "high", which decreases a desire to consume alcohol. As a result, alcoholic
patients treated with naltrexone are less likely to relapse to heavy drinking. Furthermore,
naltrexone treated patients drink fewer days and are more likely to maintain abstinence.
However, naltrexone does not have any effect on other symptoms that may contribute to
relapse such as anxiety, sleep problems and irritability. Baclofen, an FDA approved
medication for muscle spasms, may improve some of these symptoms.
Therefore, the purpose of the current study is to gather information on whether adding
baclofen to naltrexone is feasible and well tolerated.
The purpose of this research study is to learn about the use of a combination of two
medications, baclofen and naltrexone, for the treatment of alcohol dependence in men and
women ages 25-60 years old. Naltrexone is an FDA approved medication for treatment of
alcohol dependence. The most widely accepted idea for naltrexone's effect is that it reduces
the alcohol "high", which decreases a desire to consume alcohol. As a result, alcoholic
patients treated with naltrexone are less likely to relapse to heavy drinking. Furthermore,
naltrexone treated patients drink fewer days and are more likely to maintain abstinence.
However, naltrexone does not have any effect on other symptoms that may contribute to
relapse such as anxiety, sleep problems and irritability. Baclofen, an FDA approved
medication for muscle spasms, may improve some of these symptoms.
Baclofen has been studied for alcoholism in Italy in 45 individuals in two studies. In the
two Italian studies, baclofen significantly reduced alcohol withdrawal symptoms and craving
for alcohol, as well as the use of alcohol. These data have been supported by the results of
our own pilot study conducted here at UNC in 12 subjects with alcohol dependence. That study
showed that baclofen was generally well tolerated, and some individuals had significant
improvements in their drinking. Furthermore, we have recently completed enrolling 80 alcohol
dependent patients into a placebo-controlled study of baclofen and are currently analyzing
the data.
Therefore, the purpose of the current study is to gather information on whether adding
baclofen to naltrexone is feasible and well tolerated.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03340051 -
Remote Alcohol Monitoring and Episodic Thinking
|
N/A | |
Completed |
NCT02901041 -
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
|
Phase 3 | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02705898 -
Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women
|
N/A | |
Completed |
NCT02486900 -
Neurofeedback & Alcohol Dependence
|
N/A | |
Completed |
NCT02197598 -
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
|
Phase 4 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Recruiting |
NCT02385643 -
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
|
N/A | |
Completed |
NCT01828866 -
Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT02193204 -
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk
|
N/A | |
Completed |
NCT01342549 -
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
|
Phase 3 | |
Completed |
NCT01165541 -
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
|
Phase 2 | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT00585780 -
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
|
Phase 1/Phase 2 | |
Completed |
NCT01056484 -
Mindfulness Meditation for Health
|
Phase 2 | |
Completed |
NCT00607620 -
Disseminating Organizational SBI Services at Trauma Centers
|
N/A | |
Completed |
NCT00884884 -
Aripiprazole and Topiramate on Free-Choice Alcohol Use
|
Phase 2/Phase 3 | |
Completed |
NCT00463346 -
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
|
Phase 3 |